Neuroscience
From The New York Times:
F.D.A. Sees Promise in Alzheimer’s Imaging Drug
By THE ASSOCIATED PRESS
Published: January 20, 2011
Filed at 5:40 p.m. EST
Read the full report
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
A fuller report from The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By GINA KOLATA The New York Times Published: January 20, 2011 "A committee voted that the agency should approve the first test that can show the characteristic...
- Modafinil, Adhd, And The Fda
From The Washington Post: Use of Drug to Treat ADHD in Children Opposed Associated Press Friday, March 24, 2006; Page A11 The narcolepsy drug modafinil should not be approved as a treatment for attention-deficit hyperactivity disorder in children until...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Methylphenidate
From The New York Times:Panel Recommends Warnings for Ritalin and Other Stimulants By THE ASSOCIATED PRESS Published: February 9, 2006 Filed at 4:13 p.m. ET WASHINGTON (AP) -- Federal science advisers voted narrowly Thursday to recommend the most serious...
- Outcome Of Fda Meeting About Exanta
The Associated Press reported this evening about today's FDA meeting (see yesterday's post: Forthcoming Meeting...): FDA Panel Urges More Studies of Stroke Med By THE ASSOCIATED PRESS (copyright) Filed at 8:51 p.m. ET WILMINGTON, Del....
Neuroscience
FDA: PCNS Drugs Advisory Committee Results for Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times:
F.D.A. Sees Promise in Alzheimer’s Imaging Drug
By THE ASSOCIATED PRESS
Published: January 20, 2011
Filed at 5:40 p.m. EST
WASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical designed to help screen for Alzheimer's disease could be useful pending additional study and training for physicians.
The Food and Drug Administration panel of advisers voted 16-0 in favor of approval for Eli Lilly's Amyvid on the condition that the company demonstrates the images can be consistently interpreted by physicians who have received training in reading the scans.
Without those requirements the panel voted 13-3 against approval for the injection in an earlier vote. The FDA is not required to follow the panel's advice, though it often does.
Read the full report
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
A fuller report from The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By GINA KOLATA The New York Times Published: January 20, 2011 "A committee voted that the agency should approve the first test that can show the characteristic...
- Modafinil, Adhd, And The Fda
From The Washington Post: Use of Drug to Treat ADHD in Children Opposed Associated Press Friday, March 24, 2006; Page A11 The narcolepsy drug modafinil should not be approved as a treatment for attention-deficit hyperactivity disorder in children until...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Methylphenidate
From The New York Times:Panel Recommends Warnings for Ritalin and Other Stimulants By THE ASSOCIATED PRESS Published: February 9, 2006 Filed at 4:13 p.m. ET WASHINGTON (AP) -- Federal science advisers voted narrowly Thursday to recommend the most serious...
- Outcome Of Fda Meeting About Exanta
The Associated Press reported this evening about today's FDA meeting (see yesterday's post: Forthcoming Meeting...): FDA Panel Urges More Studies of Stroke Med By THE ASSOCIATED PRESS (copyright) Filed at 8:51 p.m. ET WILMINGTON, Del....